{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000076","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.241180+00:00","generated_at":"2026-06-12T02:31:51.689104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcutis Q2 2023: ZORYVE revenue $4.8M (+72% QoQ); net loss $71M","bullets":["Total revenues $5.2M; ZORYVE net product revenue $4.8M, up 72% sequentially.","Net loss $71.0M ($1.16 per share) vs $67.4M ($1.31) in Q2 2022.","Cash and marketable securities $269.6M as of June 30 vs $410.8M at Dec 31, 2022.","Commercial coverage expanded to >130M lives (all 3 largest PBMs) for ZORYVE.","FDA action date Dec 16, 2023 for roflumilast foam in seborrheic dermatitis; sNDA for atopic dermatitis expected late Q3/early Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000076","json":"https://secwatch.observer/filing/0001787306-23-000076.json","markdown":"https://secwatch.observer/filing/0001787306-23-000076.md","text":"https://secwatch.observer/filing/0001787306-23-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/arqt-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:31:51.689104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cdd913e0448930ea7f0f1ee9bde4e4ed2f1683a","claim":"Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.","evidence_excerpt":"Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update • Achieved total revenues of $5.2 million in the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"0cdd913e0448930ea7f0f1ee9bde4e4ed2f1683a","claim":"Arcutis Biotherapeutics, Inc. reported quarter ended June 30, 2023 results: revenue $4.8 million.","evidence_excerpt":"Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of 2023, driven by nearly 40% demand growth as well as gross-to-net improvement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000076/0001787306-23-000076-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Revenue","value":"$4.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}